Immune-Mediated Inflammatory Disease Forum

ベースラインMRIとCRPで層別化したX線基準を満たさない体軸性脊椎関節炎におけるセルトリズマブペゴルの有効性: C-axSpAnd 試験結果

Robinson PC,

Maksymowych WP,

Gensler LS,

Hall S,

Rudwaleit M,

Hoepken B,

Bauer L,

Kumke T,

Kim M,

de Peyrecave N,

Deodhar A

ACR Open Rheumatol. 2022 doi: 10.1002/acr2.11469

The results of this analysis indicated that certolizumab pegol (CZP) treatment benefits patients with nr-axSpA across all the MRI/CRP subgroups studied. To reach this conclusion, this study evaluated clinical responses to CZP in patients with nr-axSpA stratified by baseline MRI/CRP status.

Interestingly, responses were numerically higher in patients who were MRI+/CRP+, particularly for ASDAS-MI, but still substantial in MRI+/CRP− and MRI−/CRP+ patients. Despite having a potentially high burden of disease and the potential to respond to treatment with biologics MRI+/CRP− and MRI−/CRP+ patients are currently deemed ineligible for such treatment by some regulatory authorities.

Publications